{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:06:17Z","timestamp":1791083177387,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007526","name":"Universit\u00e9 de Tours","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007526","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107536","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T05:11:40Z","timestamp":1776575500000},"page":"107536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu\u00ae)"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-5865","authenticated-orcid":false,"given":"Emmanuel","family":"Douez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Gabant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Vidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Auvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Boursin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Dupeyrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Velge Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Denevault-Sabourin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Allard-Vannier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107536_bib0001","series-title":"Antibody-Drug Conjugates: Methods and Protocols, Methods in Molecular Biology","first-page":"301","article-title":"Physical stability studies of antibody-drug conjugates (ADCs) under stressed conditions","author":"Adem","year":"2020"},{"key":"10.1016\/j.ejps.2026.107536_bib40","series-title":"Bonnes Pratiques de Pr\u00e9paration","author":"ANSM","year":"2023"},{"key":"10.1016\/j.ejps.2026.107536_bib0002","doi-asserted-by":"crossref","first-page":"19122","DOI":"10.1021\/acs.jmedchem.5c01184","article-title":"Development of optimized exatecan-based immunoconjugates with potent antitumor efficacy in HER2-positive breast cancer","volume":"68","author":"Auvert","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107536_bib0003","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pharma.2011.07.002","article-title":"Guidelines for the practical stability studies of anticancer drugs: a European consensus conference","volume":"69","author":"Bardin","year":"2011","journal-title":"Annales Pharmaceutiques Fran\u00e7aises"},{"key":"10.1016\/j.ejps.2026.107536_bib0004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1208\/s12248-025-01169-9","article-title":"New frontiers in ADC analysis: advances in chromatography, electrophoresis, and mass spectrometry","volume":"28","author":"Beck","year":"2025","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2026.107536_bib0005","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/jms.3554","article-title":"Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies","volume":"50","author":"Beck","year":"2015","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejps.2026.107536_bib0006","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C7OB02780J","article-title":"Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody\u2013drug conjugates","volume":"16","author":"Bryden","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejps.2026.107536_bib0007","unstructured":"Burrows, L., 2018. Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures. GaBIJ. URL https:\/\/gabi-journal.net\/extended-stability-of-a-biosimilar-of-trastuzumab-ct-p6-after-reconstitution-in-vials-dilution-in-polyolefin-bags-and-storage-at-various-temperatures.html (accessed 10.21.25)."},{"key":"10.1016\/j.ejps.2026.107536_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2024.116410","article-title":"Assessment of chemical stability of monoclonal antibody and antibody drug conjugate administered by pressurized intraperitoneal aerosol chemotherapy","volume":"251","author":"D\u2019Atri","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2026.107536_bib0009","first-page":"290","article-title":"A combination of native LC-MS approaches for the comprehensive characterization of the antibody-drug conjugate trastuzumab deruxtecan","volume":"27","author":"Desligni\u00e8re","year":"2022","journal-title":"FBL"},{"key":"10.1016\/j.ejps.2026.107536_bib0010","unstructured":"DESTINY Clinical Trials for Metastatic Breast Cancer [WWW Document], n.d. URL https:\/\/destinyclinicaltrials.com\/en (accessed 10.21.25)."},{"key":"10.1016\/j.ejps.2026.107536_bib0011","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2019.03.021","article-title":"Antibody-drug conjugates- stability and formulation","volume":"139","author":"Duerr","year":"2019","journal-title":"Europ. J. Pharmac. Biopharmac."},{"key":"10.1016\/j.ejps.2026.107536_bib0012","first-page":"1","article-title":"Antibody\u2013drug conjugates come of age in oncology","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107536_bib0013","unstructured":"Enhertu | European Medicines Agency (EMA) [WWW Document], 2021. URL https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu (accessed 10.21.25)."},{"key":"10.1016\/j.ejps.2026.107536_bib0014","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.xphs.2023.10.015","article-title":"Aggregate formation and antibody stability in infusion bags: the impact of manual and robotic compounding of monoclonal antibodies","volume":"113","author":"Geersing","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107536_bib0015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/1078155220940410","article-title":"Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion","volume":"27","author":"Guyader","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejps.2026.107536_bib0016","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/j.xphs.2023.05.011","article-title":"Characterization of microbial growth potential in antibody drug IV admixtures by microbial challenge","volume":"112","author":"Hu","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107536_bib0017","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/pharmaceutics14081524","article-title":"Intra-domain cysteines (IDC), a new strategy for the development of original antibody fragment\u2013Drug conjugates (FDCs)","volume":"14","author":"Jolivet","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107536_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ph13090245","article-title":"Antibody\u2013Drug conjugates: the last decade","volume":"13","author":"Joubert","year":"2020","journal-title":"Pharmaceuticals. (Basel)"},{"key":"10.1016\/j.ejps.2026.107536_bib0019","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40259-018-0314-1","article-title":"In-use physicochemical and biological stability of the Trastuzumab biosimilar CT-P6 upon preparation for intravenous infusion","volume":"32","author":"Kim","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2026.107536_bib0020","article-title":"Focused physicochemical stability study of reconstituted trastuzumab biosimilar SB3 (Ontruzant\u00ae) stored in the original vials over 28 days","volume":"9","author":"Knoll","year":"2024","journal-title":"Pharm. Technol. Hosp. Pharm."},{"key":"10.1016\/j.ejps.2026.107536_bib0021","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejca.2020.04.042","article-title":"Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion","volume":"135","author":"Le Guyader","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejps.2026.107536_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107374","article-title":"Insight on photosensitivity of bispecific antibody-drug conjugates: rOS-mediated degradation and payload conjugation-induced structure alterations","volume":"216","author":"Liu","year":"2026","journal-title":"Europ. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejps.2026.107536_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17111397","article-title":"Insights into photo degradation and stabilization strategies of antibody\u2013Drug conjugates with Camptothecin payloads","volume":"17","author":"Luo","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107536_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115249","article-title":"Stability assessment of Polatuzumab vedotin and Brentuximab vedotin using different analytical techniques","volume":"228","author":"Mohamed","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2026.107536_bib0026","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpba.2017.12.022","article-title":"Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol","volume":"150","author":"Mohamed","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2026.107536_bib0027","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.bmcl.2016.02.020","article-title":"Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads","volume":"26","author":"Nakada","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2026.107536_bib0028","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/acs.jmedchem.4c02344","article-title":"Evaluation of dynamic light scattering as an effective quality control method for aggregates in radiolabeled antibodies","volume":"68","author":"Nguyen","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107536_bib0029","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: a practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2026.107536_bib0024","first-page":"220","article-title":"Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin\u00ae), intravenous solutions","volume":"14","author":"Pabari","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejps.2026.107536_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108192","article-title":"Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics","volume":"67","author":"Pang","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejps.2026.107536_bib0031","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/pharmacy13010022","article-title":"A physicochemical stability study of pembrolizumab vial leftovers: let us stop pouring good money down the drain","volume":"13","author":"Porlier","year":"2025","journal-title":"Pharmacy"},{"key":"10.1016\/j.ejps.2026.107536_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.144177","article-title":"Increasing the developability of lambda chain antibodies: engineering to confer protein L binding activity and its consequences","volume":"313","author":"Prado-Costa","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejps.2026.107536_bib0033","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.xphs.2015.11.037","article-title":"Physical and chemical stability of antibody drug conjugates: current status","volume":"105","author":"Ross","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107536_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114867","article-title":"Payload-dependent photostability of antibody-drug conjugates","volume":"216","author":"Thiess","year":"2025","journal-title":"Europ. J. Pharmaceut. Biopharmaceut."},{"key":"10.1016\/j.ejps.2026.107536_bib0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pharma.2013.06.002","article-title":"SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update","volume":"71","author":"Vigneron","year":"2013","journal-title":"Annales Pharmaceutiques Fran\u00e7aises"},{"key":"10.1016\/j.ejps.2026.107536_bib0036","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/19420862.2017.1412025","article-title":"Challenges and new frontiers in analytical characterization of antibody-drug conjugates","volume":"10","author":"Wagh","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.ejps.2026.107536_bib0037","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1021\/bc900434c","article-title":"Physicochemical stability of the antibody\u2212drug Conjugate Trastuzumab-DM1: changes due to modification and conjugation processes","volume":"21","author":"Wakankar","year":"2010","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejps.2026.107536_bib0038","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s12325-019-00973-y","article-title":"Extended stability of reconstituted and diluted SB3 (Trastuzumab Biosimilar) assessed by physicochemical and biological properties","volume":"36","author":"Yun","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejps.2026.107536_bib0039","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1021\/acs.bioconjchem.5c00485","article-title":"Photostability of topoisomerase I inhibitor conjugated IgG1 antibody\u2013Drug conjugates: characterization study and degradation mechanism analysis","volume":"36","author":"Zhou","year":"2025","journal-title":"Bioconjugate Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:50:19Z","timestamp":1779709819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":40,"alternative-id":["S0928098726001107"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107536","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hospital in-use evaluation of the physical, chemical and affinity stability of the antibody-drug conjugate trastuzumab deruxtecan (Enhertu\u00ae)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107536"}}